Elucidating the specific pharmacological mechanism of action (MOA) of Obviously occurring compounds can be difficult. Although Tarselli et al. (60) developed the 1st de novo artificial pathway to conolidine and showcased this Obviously developing compound effectively suppresses responses to each chemically induced and inflammation-derived pain, the